ERBB4
protein-codingerb-b2 receptor tyrosine kinase 4, the group of Erb-b2 receptor tyrosine kinases|MicroRNA protein coding host genes
Gene summary
This gene is a member of the Tyr protein kinase family and the epidermal growth factor receptor subfamily. It encodes a single-pass type I membrane protein with multiple cysteine rich domains, a transmembrane domain, a tyrosine kinase domain, a phosphotidylinositol-3 kinase binding site and a PDZ domain binding motif. The protein binds to and is activated by neuregulins and other factors and induces a variety of cellular responses including mitogenesis and differentiation. Multiple proteolytic events allow for the release of a cytoplasmic fragment and an extracellular fragment. Mutations in this gene have been associated with cancer. Alternatively spliced variants which encode different protein isoforms have been described; however, not all variants have been fully characterized. [provided by RefSeq, Jul 2008]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~1,163.1 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AD
Disease ID:MONDO:0001071
Submitter: PanelApp Australia
Inheritance Pattern: AD
Disease ID:MONDO:0014223
Submitter: Genomics England PanelApp
Inheritance Pattern: AD
Disease ID:MONDO:0004976
Submitter: Orphanet
Inheritance Pattern: AD
Disease ID:MONDO:0014223
Submitter: ClinGen
ERBB4 was first reported in relation to autosomal dominant amyotrophic lateral sclerosis 19 (meaning amyotrophic lateral sclerosis caused by variants in the ERBB4 gene rather than a distinct ALS phenotype) in 2013 (Takahashi et al., PMID:24119685). Amyotrophic lateral sclerosis (ALS) is a progressive, neurodegenerative disease involving death or loss of function of upper and lower motor neurons. ERBB4 is a membrane-bound receptor tyrosine kinase which binds ligands such as neuregulin, dimerises, usually with ErbB2 or ErbB3, and auto-phosphorylates on activation. At least 19 unique ERBB4 variants have been reported in humans. Evidence supporting this gene-disease relationship includes case-level and experimental data. 2.9 points have been given for variants in this gene which have been reported in at least 7 publications (PMIDs: 24119685; 32065797; 32166880; 33414559; 31788332; 31432357; 28889094). The seminal paper (Takahashi et al., 2013 PMID:24119685) identified ERBB4 as a candidate gene in a family of 3 affected siblings, based on an assumption of reduced penetrance. A de novo variant in ERBB4 in a person with sporadic ALS was identified as part of this study. Other publications consist of a case study of an individual with ALS-FTD, and genetic epidemiology studies involving genotyping people enrolled in specialist ALS clinics and screening for variants in known or implicated ALS genes. The mechanism for disease is unknown. This gene-disease association is supported by an immunohistochemistry study (PMID: 31124187) investigating ErbB4 expression in the central nervous system of people with sporadic ALS compared to non-neuro disease controls and neuro disease controls. The study showed there was reduced ErbB4 in motor neurons correlating with severity of motor neuron loss, that the subcellular localization of ErbB4 was altered in people with sporadic ALS – ErbB4 was found in the nucleolus, in spheroids (previously associated with ALS pathogenicity) and in glial cells. There was a negative correlation between pathogenic subcellular localization of TDP-43 and presence of ErbB4 in motor neurons. ERBB4 mouse knock-out models produce an altered neuronal phenotype, but not an ALS phenotype (PMIDs: 14555954; 12824469; 15543145; 15976301).
Inheritance Pattern: AD
Disease ID:MONDO:0014223
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AD
Disease ID:MONDO:0014223
Submitter: Ambry Genetics
Clinical Genomic Database (CGD)
Manifestation: Neurologic
Intervention: General
Rationale: Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to ERBB4 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_005235.3. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 6 | 139 | 10 | 155 | ||
| missense | 1 | 4 | 315 | 21 | 341 | |
| nonsense | 1 | 4 | 5 | |||
| start loss | 0 | |||||
| frameshift | 2 | 1 | 6 | 9 | ||
| splice donor/acceptor (+/-2bp) | 3 | 11 | 14 | |||
| Total | 3 | 9 | 342 | 160 | 10 | 524 |
Highest pathogenic variant AF is 0.00003469873
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_005226.1 | 28 | MANE Select | |
| Ensembl | ENSP00000342235.4 | 28 | MANE Select | |
| RefSeq | NP_001036064.1 | 27 | Standard | |
| RefSeq | NP_001425934.1 | 28 | Standard |
Model Organisms & Knockout Phenotypes
Observed phenotypic effects in mouse and zebrafish models
| Gene / Model | Organism | Observed Phenotype |
|---|---|---|
| erbb4a | Danio rerio | Structure: optic tectum Quality: decreased process quality abnormal |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- PI3K-Akt signaling pathway - Homo sapiens (human)
- ErbB signaling pathway - Homo sapiens (human)
- Calcium signaling pathway - Homo sapiens (human)
- MAPK signaling pathway - Homo sapiens (human)
- Proteoglycans in cancer - Homo sapiens (human)
Biological Process
- MAPK cascade
- neural crest cell migration
- positive regulation of protein phosphorylation
- signal transduction
- transmembrane receptor protein tyrosine kinase signaling pathway
Molecular Function
- protein tyrosine kinase activity
- transmembrane receptor protein tyrosine kinase activity
- Ras guanyl-nucleotide exchange factor activity
- epidermal growth factor receptor binding
- protein binding
Cellular Component
- extracellular region
- nucleus
- nucleoplasm
- mitochondrion
- mitochondrial matrix
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000342788
- Coding exons
- 28
- Length
- 1163120
- Individuals with no LoFs
- 125729
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 19
- Defined
- 125748
- p
- 0.0000756
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 2.01 | 576 | 729 | 0.790 | 0.0000394 | 8616 |
| Missense (PolyPhen) | 119 | 218.55 | 0.54451 | 2633 | ||
| Synonymous | -2.23 | 300 | 255 | 1.18 | 0.0000134 | 2472 |
| Loss of Function | 6.63 | 12 | 73.3 | 0.164 | 0.00000404 | 850 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.00018 | 0.00018 | rare |
| Latino/Admixed American | 0.000029 | 0.000029 | rare |
| Ashkenazi Jewish | 0.000099 | 0.000099 | rare |
| East Asian | 0.00022 | 0.00022 | rare |
| Finnish | 0.000092 | 0.000092 | rare |
| European (Non-Finnish) | 0.000044 | 0.000044 | rare |
| South Asian | 0.000098 | 0.000098 | rare |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins and EGF family members and regulates development of the heart, the central nervous system and the mammary gland, gene transcription, cell proliferation, differentiation, migration and apoptosis. Required for normal cardiac muscle differentiation during embryonic development, and for postnatal cardiomyocyte proliferation. Required for normal development of the embryonic central nervous system, especially for normal neural crest cell migration and normal axon guidance. Required for mammary gland differentiation, induction of milk proteins and lactation. Acts as cell-surface receptor for the neuregulins NRG1, NRG2, NRG3 and NRG4 and the EGF family members BTC, EREG and HBEGF. Ligand binding triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors. Ligand specificity and signaling is modulated by alternative splicing, proteolytic processing, and by the formation of heterodimers with other ERBB family members, thereby creating multiple combinations of intracellular phosphotyrosines that trigger ligand- and context-specific cellular responses. Mediates phosphorylation of SHC1 and activation of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Isoform JM-A CYT-1 and isoform JM-B CYT-1 phosphorylate PIK3R1, leading to the activation of phosphatidylinositol 3-kinase and AKT1 and protect cells against apoptosis. Isoform JM-A CYT-1 and isoform JM-B CYT-1 mediate reorganization of the actin cytoskeleton and promote cell migration in response to NRG1. Isoform JM-A CYT-2 and isoform JM-B CYT-2 lack the phosphotyrosine that mediates interaction with PIK3R1, and hence do not phosphorylate PIK3R1, do not protect cells against apoptosis, and do not promote reorganization of the actin cytoskeleton and cell migration. Proteolytic processing of isoform JM-A CYT-1 and isoform JM-A CYT-2 gives rise to the corresponding soluble intracellular domains (4ICD) that translocate to the nucleus, promote nuclear import of STAT5A, activation of STAT5A, mammary epithelium differentiation, cell proliferation and activation of gene expression. The ERBB4 soluble intracellular domains (4ICD) colocalize with STAT5A at the CSN2 promoter to regulate transcription of milk proteins during lactation. The ERBB4 soluble intracellular domains can also translocate to mitochondria and promote apoptosis. {ECO:0000269|PubMed:10348342, ECO:0000269|PubMed:10353604, ECO:0000269|PubMed:10358079, ECO:0000269|PubMed:10722704, ECO:0000269|PubMed:10867024, ECO:0000269|PubMed:11178955, ECO:0000269|PubMed:11390655, ECO:0000269|PubMed:12807903, ECO:0000269|PubMed:15534001, ECO:0000269|PubMed:15746097, ECO:0000269|PubMed:16251361, ECO:0000269|PubMed:16778220, ECO:0000269|PubMed:16837552, ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:17638867, ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:20858735, ECO:0000269|PubMed:8383326, ECO:0000269|PubMed:8617750, ECO:0000269|PubMed:9135143, ECO:0000269|PubMed:9168115, ECO:0000269|PubMed:9334263}.;
- Disease
- DISEASE: Amyotrophic lateral sclerosis 19 (ALS19) [MIM:615515]: A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5- 10% of the cases. {ECO:0000269|PubMed:24119685}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.402
Intolerance Scores
- LoFtool
- 0.147
- RVIS EVS
- -1.97
- RVIS percentile EVS
- 1.79
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- E
- Indispensability score
- 0.975
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |